SG Americas Securities
AXSM icon

SG Americas Securities’s Axsome Therapeutics AXSM Stock Holding History

SG Americas Securities’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Sell
7,392
-10,289
-58% -$1.78M ﹤0.01% 1616
2025
Q4 		$3.23M Buy
17,681
+5,584
+46% +$780K ﹤0.01% 1289
2025
Q3 		$1.47M Buy
12,097
+5,368
+80% +$605K 0.01% 1155
2025
Q2 		$702K Buy
6,729
+3,978
+145% +$421K ﹤0.01% 1420
2025
Q1 		$321K Sell
2,751
-801
-23% -$91.3K ﹤0.01% 2154
2024
Q4 		$301K Sell
3,552
-8,001
-69% -$736K ﹤0.01% 1791
2024
Q3 		$1.04M Buy
+11,553
New +$1.01M ﹤0.01% 1059
2024
Q2 		– Sell
-15,104
Closed -$1.21M – 2854
2024
Q1 		$1.21M Buy
15,104
+12,963
+605% +$1.09M 0.01% 1071
2023
Q4 		$170K Buy
+2,141
New +$143K ﹤0.01% 2312
2023
Q2 		– Sell
-13,269
Closed -$818K – 2315
2023
Q1 		$818K Buy
13,269
+11,561
+677% +$760K 0.01% 1295
2022
Q4 		$132K Sell
1,708
-12,154
-88% -$726K ﹤0.01% 2522
2022
Q3 		$619K Buy
13,862
+5,412
+64% +$270K 0.01% 1354
2022
Q2 		$324K Sell
8,450
-23,760
-74% -$751K ﹤0.01% 2333
2022
Q1 		$1.33M Sell
32,210
-1,033
-3% -$32K 0.01% 1221
2021
Q4 		$1.26M Sell
33,243
-49,823
-60% -$1.83M 0.01% 1467
2021
Q3 		$2.74M Buy
83,066
+39,559
+91% +$1.54M 0.01% 1004
2021
Q2 		$2.94M Sell
43,507
-10,843
-20% -$651K 0.01% 891
2021
Q1 		$3.08M Buy
54,350
+2,119
+4% +$149K 0.02% 764
2020
Q4 		$4.25M Buy
52,231
+32,423
+164% +$2.42M 0.02% 590
2020
Q3 		$1.41M Buy
19,808
+5,319
+37% +$414K 0.01% 989
2020
Q2 		$1.19M Buy
14,489
+2,559
+21% +$197K 0.01% 1249
2020
Q1 		$702K Buy
11,930
+6,864
+135% +$559K 0.01% 1545
2019
Q4 		$524K Buy
+5,066
New +$205K ﹤0.01% 1729
2019
Q3 		– Sell
-6,478
Closed -$167K – 2995
2019
Q2 		$167K Buy
+6,478
New +$130K ﹤0.01% 2526
2017
Q2 		– Sell
-35,734
Closed -$139K – 3177
2017
Q1 		$139K Buy
+35,734
New +$171K ﹤0.01% 2720

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG Americas Securities's AXSM Position: Q1 2026 in Review

SG Americas Securities reduced its Axsome Therapeutics (AXSM) stake by 58% in Q1 2026, selling an estimated $1.78M and leaving 7,392 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

SG Americas Securities first reported a position in AXSM in Q1 2017 and has held it in 25 quarters since. The position peaked at $4.25M in Q4 2020. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • SG Americas Securities held 7,392 shares of Axsome Therapeutics worth $1.25M as of Q1 2026.
  • SG Americas Securities sold 10,289 Axsome Therapeutics shares in Q1 2026, an estimated $1.78M.
  • Axsome Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1616 holding.
  • SG Americas Securities first reported a position in Axsome Therapeutics in Q1 2017 and has held it in 25 quarters since.
  • SG Americas Securities's Axsome Therapeutics position peaked at $4.25M in Q4 2020.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.